Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -695.72% is 28% above its 1-year average of -962.66%, near the high end of its 1-year range (-1083.15%–-695.72%).
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-695.72%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Generate Biomedicines, Inc.
Market Cap
$1.78B
EBITDA Margin
-695.72%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.78B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$1.76B
EBITDA Margin
1.15%
TTM Avg
-0.80%
3Y Avg
-3.79%
5Y Avg
-4.67%
Market Cap
$1.71B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.87B
EBITDA Margin
-864.28%
TTM Avg
-1007.63%
3Y Avg
-1530.50%
5Y Avg
-1530.50%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$1.66B
EBITDA Margin
-164.52%
TTM Avg
-214.39%
3Y Avg
-473.06%
5Y Avg
-473.06%
Market Cap
$1.65B
EBITDA Margin
19.54%
TTM Avg
15.33%
3Y Avg
15.07%
5Y Avg
12.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.78B | -695.72% | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.78B | -628.14% | -766.74% | -948.44% | -801.32% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.76B | 1.15% | -0.80% | -3.79% | -4.67% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 3.91% | 4.83% | 6.92% | 8.21% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | 16.41% | 1.22% | -1.65% | 4.31% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.87B | -864.28% | -1007.63% | -1530.50% | -1530.50% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.66B | -164.52% | -214.39% | -473.06% | -473.06% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 19.54% | 15.33% | 15.07% | 12.91% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 0.06% | -4.29% | -15.38% | -22.40% |
Gross Margin
100.0%
EBITDA Margin
-695.7%
Operating Margin
-737.0%
Net Margin
-637.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1083.15% |
| 2026-03-31 | -842.18% |
